Anti Inflammatory News and Research

RSS

Lung physiology and immune function could spare children from severe COVID-19

Differences in lung physiology and immune function in children could be why they are more often spared from severe illness associated with COVID-19 than adults, according to pediatric and adult physicians at The University of Texas Health Science Center at Houston and Baylor College of Medicine, who teamed up to investigate the disparity.

8 Jul 2020

UC Santa Cruz- led research center focuses on botanical natural products

Although millions of people take plant-based dietary supplements or herbal medicines, understanding the effects of these natural products on human health has proven to be extremely challenging.

8 Jul 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

Study reveals how overactive immune cells aggravate heart valve disease

A new study using organ-on-a-chip technology reveals how overactive immune cells aggravate heart valve disease and how this damaging hyperactivity could potentially be controlled.

8 Jul 2020

Study: Cellular therapy can improve critical cases of COVID-19

A cellular therapy tested on 13 intubated patients with mechanical ventilation has shown to be efficient for the clinical improvement of critical cases of COVID-19.

8 Jul 2020

Corn-based diet with flavonoids alleviates IBD-like symptoms in mice

Flavonoids from a specific line of corn act as anti-inflammatory agents in the guts of mice with an inflammatory-bowel-disease-like condition, according to a team of researchers who said flavonoid-rich corn should be studied to determine its potential to provide a protective effect on human health.

7 Jul 2020

Dutch trial of convalescent plasma in COVID-19 discontinued

Now, a recent trial published on the preprint server medRxiv* in July 2020 reports that a majority of hospitalized COVID-19 patients have a high titer of neutralizing antibodies, at the time of admission, within 10 days of symptomatic disease.

7 Jul 2020

Doping agent Epo could be effective against Covid-19

Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against Covid-19.

6 Jul 2020

Researchers develop new coatings for implants to make them more compatible

New coatings on implants could help make them more compatible. Researchers at the Martin Luther University Halle-Wittenberg (MLU) have developed a new method of applying anti-inflammatory substances to implants in order to inhibit undesirable inflammatory reactions in the body.

30 Jun 2020

Overactive neutrophils may drive life-threatening blood clots in some COVID-19 patients

Scientists have new evidence that overactive neutrophils--a common type of circulating immune cell--may drive the life-threatening blood clots and inflammation that occur in some patients with COVID-19.

29 Jun 2020

RCSI begins clinical trial of promising therapy for critically ill COVID-19 patients

Clinician scientists at RCSI University of Medicine and Health Sciences have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care.

29 Jun 2020

Integrating pharmacists into GP practices can optimize treatment plans in primary care

Research undertaken by RCSI University of Medicine and Health Sciences suggests that integrating pharmacists into general practice (GP) teams facilitates collaboration to optimize treatment plans for patients with long-term medical needs and alleviate pressures on GP practices.

29 Jun 2020

A novel strategy to achieve site-selective chiral drug synthesis in living systems

Enantioselectivity plays an important role in the pharmacological and toxicological processes of chiral drugs.

26 Jun 2020

Pixatimod is active in lab studies against SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulating the world has caused over 9.6 million cases and over 490,000 deaths as of June 26, 2020. With neither an effective vaccine nor therapeutic drug yet available, intensive and widespread research is ongoing to develop a pharmacological intervention that will halt the global pandemic.

25 Jun 2020

Protein profile in serum reflects COVID-19 severity

The wide range of manifestations of COVID-19 has continued to baffle investigators. Now, a new study published on the preprint server medRxiv in June 2020 shows that blood proteins in COVID-19 patients change over time, and these can possibly predict or reflect the severity of disease. More, they may present targets for treatment.

25 Jun 2020

Immune response variations across the COVID-19 spectrum

A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.

25 Jun 2020

New method could safeguard water quality, environment and health

A research team at Swansea University have developed a new method for fast removal and detection of wastewater pollutants that come from everyday pharmaceuticals like paracetamol, ibuprofen and aspirin, which could help minimize their impact on the environment.

24 Jun 2020

Research shows females use anti-inflammatory T cells to maintain their blood pressure

In the face of a multipronged front to drive blood pressure up, including a high-salt diet, females are better able to keep their pressure down by increasing levels of a T cell that selectively dials back inflammation, scientists say.

23 Jun 2020

Manipulating macrophages could be a viable strategy for treating cancer

Most traditional cancer therapies target either the tumor cells themselves or indiscriminately kill any rapidly dividing cell.

22 Jun 2020

New therapy provides relief in patients with chronic low back pain

A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide.

19 Jun 2020